Vadim Kemaykin
Research Subjects
Vadim Kemaykin has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Azat Karabekov
National Research Oncology Center
4 shared publications - Aleksandr Kolesnev
National Research Oncology Center
3 shared publications - Jamilya Saparbay
School of Medicine, Nazarbayev University, Kerey and Zhanibek Khans Street 5, Astana 010000, Kazakhstan
3 shared publications - A.S. Suleimenova
National Research Oncology Center
2 shared publications - Ainura Galiakbarova
National Research Oncology Center
2 shared publications - Dinara Zharlyganova
National Center for Biotechnology, Korgalzhin hwy 13/5, Astana 010000, Kazakhstan
2 shared publications
Latest Publications
- 23 October 2026
- Published by NpJSC "Astana Medical University" in Astana Medical Journal
- Vol. 126 (5)
Critical complications of CAR T-cell therapy: an interdisciplinary approach to early diagnosis and critical care
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed and refractory hematologic malignancies but can cause rapidly progressive inflammatory, neurologic, infectious, hematologic, cardiovascular, respiratory, and renal complications with overlapping clinical manifestations. This review aimed to synthesize current evidence on their early diagnosis, monitoring, critical care, and interdisciplinary management. A targeted narrative search was conducted in PubMed, including MEDLINE-indexed records, Google Scholar, and websites of international professional societies; the last search was performed on 30 September 2026. The structured PubMed strategy retrieved 4,178 records. Publications from January 2016 through September 2026 were considered, together with two earlier foundational guidelines on febrile neutropenia and acute kidney injury. Thirty-five sources were included after title/abstract screening and targeted full-text assessment. The review addresses cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, infection and sepsis, acute organ dysfunction, prolonged cytopenias, and secondary immunodeficiency. Standardized toxicity grading, serial neurologic assessment, and continuous evaluation of hemodynamics, oxygenation, fluid balance, renal function, coagulation, ferritin, fibrinogen, blood cell counts, and microbiological findings are central to early recognition of deterioration. Fever and organ dysfunction require simultaneous evaluation for immune-mediated toxicity and infection because these conditions may coexist and no single biomarker reliably excludes sepsis. Management should combine syndrome-directed anti-inflammatory treatment, prompt empirical antimicrobial therapy when indicated, and timely organ support. Advanced support outside the intensive care unit is an organizational exception rather than an evidence-proven equivalent model and must not delay transfer. Predefined escalation pathways and coordinated multidisciplinary care are essential for safe implementation of CAR T-cell therapy. Keywords: receptors, chimeric antigen, immunotherapy, adoptive, cytokine release syndrome, neurotoxicity syndromes, critical care, sepsis, patient care team.
- 23 October 2026
- Published by NpJSC "Astana Medical University" in Astana Medical Journal
- Vol. 126 (5)
Critical complications of CAR T-cell therapy: an interdisciplinary approach to early diagnosis and critical care
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed and refractory hematologic malignancies but can cause rapidly progressive inflammatory, neurologic, infectious, hematologic, cardiovascular, respiratory, and renal complications with overlapping clinical manifestations. This review aimed to synthesize current evidence on their early diagnosis, monitoring, critical care, and interdisciplinary management. A targeted narrative search was conducted in PubMed, including MEDLINE-indexed records, Google Scholar, and websites of international professional societies; the last search was performed on 30 September 2026. The structured PubMed strategy retrieved 4,178 records. Publications from January 2016 through September 2026 were considered, together with two earlier foundational guidelines on febrile neutropenia and acute kidney injury. Thirty-five sources were included after title/abstract screening and targeted full-text assessment. The review addresses cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, infection and sepsis, acute organ dysfunction, prolonged cytopenias, and secondary immunodeficiency. Standardized toxicity grading, serial neurologic assessment, and continuous evaluation of hemodynamics, oxygenation, fluid balance, renal function, coagulation, ferritin, fibrinogen, blood cell counts, and microbiological findings are central to early recognition of deterioration. Fever and organ dysfunction require simultaneous evaluation for immune-mediated toxicity and infection because these conditions may coexist and no single biomarker reliably excludes sepsis. Management should combine syndrome-directed anti-inflammatory treatment, prompt empirical antimicrobial therapy when indicated, and timely organ support. Advanced support outside the intensive care unit is an organizational exception rather than an evidence-proven equivalent model and must not delay transfer. Predefined escalation pathways and coordinated multidisciplinary care are essential for safe implementation of CAR T-cell therapy. Keywords: receptors, chimeric antigen, immunotherapy, adoptive, cytokine release syndrome, neurotoxicity syndromes, critical care, sepsis, patient care team.
- 27 February 2026
- Published by NpJSC "Astana Medical University" in Astana Medical Journal
- Vol. 126 (1) , amj002
Impact of CD56 Expression on Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma
Background.Multiple myeloma (MM) is a heterogeneous hematologic malignancy with variable clinical course and response to therapy [1,2]. Unfortunately, MM is still an incurable disease, and the difference in overallsurvival(OS) and progressive free surviva l (PFS) rates in patients varies depending on the risk group. Due to the limited access to high-tech molecular genetic studies for risk group stratification, it remains relevant to study more accessible prognostic markers, in particular based on flow cytometry data [1,8].Aim.In our study, our goal was to evaluate the level of CD56 expression on pathological plasma cells and their effect on the frequency of objective response to induction therapy and overall survival rates in patients with newly diagnosed MM.Materials and Methods.We conducted a retrospective single-center analysis of 26 newly diagnosed MM patients treated at the National Research Oncology Center in Astana, Kazakhstan. For immunophenotyping of plasma cells, we employed multicolor flow cytometry following the standardized EuroFlow protocol with its recommended antibody panels[7,17]. Only patients with ≥10% clonal plasma cells and an aberrant immunophenotype were included, in accordance with international recommendations [4,7,13]. Patients were stratified according to CD56 expression level. All patients received VCD induction therapy. Response was evaluated according to IMWG criteria, and OS was analyzed using Kaplan–Meier curves [3,11]. Results.High objective response rates and 100% overall survival at 24 months were observed in patients with CD56 expression ≤30%, while patients with negative CD56 expression and those with CD56 expression >30% were more likely to experience primary refractoriness and a tendency toward lower overall survival. However, in our study, the differences did not reach statistical significance (p=0.31), possibly due to the limited patient sample, but we do see a trend toward worse outcomes.Conclusion.CD56 expression is an accessible additional prognostic marker and may be used for treatment personalization in patients with multiple myeloma.Keywords:multiple myeloma, CD56, flow cytometry, immunophenotyping, prognosis.
- 27 February 2026
- Published by NpJSC "Astana Medical University" in Astana Medical Journal
- Vol. 126 (1) , amj002
Impact of CD56 Expression on Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma
Background.Multiple myeloma (MM) is a heterogeneous hematologic malignancy with variable clinical course and response to therapy [1,2]. Unfortunately, MM is still an incurable disease, and the difference in overallsurvival(OS) and progressive free surviva l (PFS) rates in patients varies depending on the risk group. Due to the limited access to high-tech molecular genetic studies for risk group stratification, it remains relevant to study more accessible prognostic markers, in particular based on flow cytometry data [1,8].Aim.In our study, our goal was to evaluate the level of CD56 expression on pathological plasma cells and their effect on the frequency of objective response to induction therapy and overall survival rates in patients with newly diagnosed MM.Materials and Methods.We conducted a retrospective single-center analysis of 26 newly diagnosed MM patients treated at the National Research Oncology Center in Astana, Kazakhstan. For immunophenotyping of plasma cells, we employed multicolor flow cytometry following the standardized EuroFlow protocol with its recommended antibody panels[7,17]. Only patients with ≥10% clonal plasma cells and an aberrant immunophenotype were included, in accordance with international recommendations [4,7,13]. Patients were stratified according to CD56 expression level. All patients received VCD induction therapy. Response was evaluated according to IMWG criteria, and OS was analyzed using Kaplan–Meier curves [3,11]. Results.High objective response rates and 100% overall survival at 24 months were observed in patients with CD56 expression ≤30%, while patients with negative CD56 expression and those with CD56 expression >30% were more likely to experience primary refractoriness and a tendency toward lower overall survival. However, in our study, the differences did not reach statistical significance (p=0.31), possibly due to the limited patient sample, but we do see a trend toward worse outcomes.Conclusion.CD56 expression is an accessible additional prognostic marker and may be used for treatment personalization in patients with multiple myeloma.Keywords:multiple myeloma, CD56, flow cytometry, immunophenotyping, prognosis.
- 15 December 2025
- Published by Australasia Publishing Group in Oncology, Nuclear Medicine and Transplantology
- Vol. 1 (2) , onmt012
Diagnosis and Treatment of HHV-8–Associated Multicentric Castleman Disease: a Clinical Case From the National Scientific Oncology Center
Castleman disease (CD) is a rare lymphoproliferative disorder with heterogeneous clinical manifestations. This article presents a clinical case of HHV-8–associated multicentric Castleman disease (MCD) in an HIV-negative patient treated at the National Scientific Oncology Center. Diagnostic methods included histological and immunohistochemical evaluation, laboratory investigations, and imaging studies. The choice of therapy is discussed. The patient demonstrated resistance to rituximab monotherapy but achieved a favorable response to R-CHOP chemotherapy. This case highlights the importance of early assessment of HHV-8 status and an individualized approach to treatment selection.
- 15 December 2025
- Published by Australasia Publishing Group in Oncology, Nuclear Medicine and Transplantology
- Vol. 1 (2) , onmt012
Diagnosis and Treatment of HHV-8–Associated Multicentric Castleman Disease: a Clinical Case From the National Scientific Oncology Center
Castleman disease (CD) is a rare lymphoproliferative disorder with heterogeneous clinical manifestations. This article presents a clinical case of HHV-8–associated multicentric Castleman disease (MCD) in an HIV-negative patient treated at the National Scientific Oncology Center. Diagnostic methods included histological and immunohistochemical evaluation, laboratory investigations, and imaging studies. The choice of therapy is discussed. The patient demonstrated resistance to rituximab monotherapy but achieved a favorable response to R-CHOP chemotherapy. This case highlights the importance of early assessment of HHV-8 status and an individualized approach to treatment selection.
- Open Access
- 12 November 2025
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 77 (3) , 50-56
SUCCESSFUL EXPERIENCE WITH FAECAL MICROBIOTA TRANSPLANTATION IN A PATIENT WITH MYELODYSPLASTIC SYNDROME AND GRAFT-VERSUS-HOST REACTION WITH INTESTINAL LESIONS COMBINED WITH ENTEROCOLITIS CAUSED BY CLOSTRIDIUM DIFFICILE INFECTION: A CLINICAL CASE
Relevance: Faecal microbiota transplantation (FMT) is the transfer of intestinal contents from a healthy donor to a patient to restore normal microflora. The material contains beneficial bacteria, fungi, antibodies, prebiotics, and other biologically active components. FMT is most effectively used for recurrent Clostridium difficile infection, showing better results compared to traditional treat-ment, such as vancomycin. Studies also suggest the potential of FMT in treating inflammatory bowel diseases, obesity, metabolic syndrome, and gastrointestinal tract functional disorders. In recent years, the method has gained widespread recognition and is now considered a potential first-line therapy for Clostridium difficile. The study aimed to present the first successful clinical experience of faecal microbiota transplanta-tion in a patient with myelodysplastic syndrome and graft-versus-host disease, characterized by in-testinal lesions. Methods: A clinical case of a 46-year-old patient who underwent allogeneic bone marrow trans-plantation for myelodysplastic syndrome is described. In the early post-transplantation period, the patient developed severe manifestations of Graft-versus-host disease (GvHD) with predominant in-volvement of the gastrointestinal tract: severe diarrhoea, abdominal pain, weight loss, signs of dysbiosis, and nutritional deficiency. After ineffective therapy with steroids and supportive care, a decision was made to perform FMT using carefully selected donor material. Results. The FMT procedure was clinically successful, with improvements in general condition, a decrease in the severity of diarrhea, stabilization of body weight, and restoration of appetite noted within several days. Endoscopic and histological examinations of the intestinal mucosa confirmed a reduction in inflammatory changes. No side effects, complications, or signs of systemic infection were recorded after FMT. Conclusions. The successful application of FMT in this case demonstrates the potential of the meth-od as an additional therapeutic tool in (GvHD) with intestinal involvement, particularly in steroid-resistant forms of the disease
- 12 November 2025
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 77 (3) , 50-56
Open AccessSUCCESSFUL EXPERIENCE WITH FAECAL MICROBIOTA TRANSPLANTATION IN A PATIENT WITH MYELODYSPLASTIC SYNDROME AND GRAFT-VERSUS-HOST REACTION WITH INTESTINAL LESIONS COMBINED WITH ENTEROCOLITIS CAUSED BY CLOSTRIDIUM DIFFICILE INFECTION: A CLINICAL CASE
Relevance: Faecal microbiota transplantation (FMT) is the transfer of intestinal contents from a healthy donor to a patient to restore normal microflora. The material contains beneficial bacteria, fungi, antibodies, prebiotics, and other biologically active components. FMT is most effectively used for recurrent Clostridium difficile infection, showing better results compared to traditional treat-ment, such as vancomycin. Studies also suggest the potential of FMT in treating inflammatory bowel diseases, obesity, metabolic syndrome, and gastrointestinal tract functional disorders. In recent years, the method has gained widespread recognition and is now considered a potential first-line therapy for Clostridium difficile. The study aimed to present the first successful clinical experience of faecal microbiota transplanta-tion in a patient with myelodysplastic syndrome and graft-versus-host disease, characterized by in-testinal lesions. Methods: A clinical case of a 46-year-old patient who underwent allogeneic bone marrow trans-plantation for myelodysplastic syndrome is described. In the early post-transplantation period, the patient developed severe manifestations of Graft-versus-host disease (GvHD) with predominant in-volvement of the gastrointestinal tract: severe diarrhoea, abdominal pain, weight loss, signs of dysbiosis, and nutritional deficiency. After ineffective therapy with steroids and supportive care, a decision was made to perform FMT using carefully selected donor material. Results. The FMT procedure was clinically successful, with improvements in general condition, a decrease in the severity of diarrhea, stabilization of body weight, and restoration of appetite noted within several days. Endoscopic and histological examinations of the intestinal mucosa confirmed a reduction in inflammatory changes. No side effects, complications, or signs of systemic infection were recorded after FMT. Conclusions. The successful application of FMT in this case demonstrates the potential of the meth-od as an additional therapeutic tool in (GvHD) with intestinal involvement, particularly in steroid-resistant forms of the disease
- Open Access
- 12 November 2025
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 77 (3) , 50-56
SUCCESSFUL EXPERIENCE WITH FAECAL MICROBIOTA TRANSPLANTATION IN A PATIENT WITH MYELODYSPLASTIC SYNDROME AND GRAFT-VERSUS-HOST REACTION WITH INTESTINAL LESIONS COMBINED WITH ENTEROCOLITIS CAUSED BY CLOSTRIDIUM DIFFICILE INFECTION: A CLINICAL CASE
Relevance: Faecal microbiota transplantation (FMT) is the transfer of intestinal contents from a healthy donor to a patient to restore normal microflora. The material contains beneficial bacteria, fungi, antibodies, prebiotics, and other biologically active components. FMT is most effectively used for recurrent Clostridium difficile infection, showing better results compared to traditional treat-ment, such as vancomycin. Studies also suggest the potential of FMT in treating inflammatory bowel diseases, obesity, metabolic syndrome, and gastrointestinal tract functional disorders. In recent years, the method has gained widespread recognition and is now considered a potential first-line therapy for Clostridium difficile. The study aimed to present the first successful clinical experience of faecal microbiota transplanta-tion in a patient with myelodysplastic syndrome and graft-versus-host disease, characterized by in-testinal lesions. Methods: A clinical case of a 46-year-old patient who underwent allogeneic bone marrow trans-plantation for myelodysplastic syndrome is described. In the early post-transplantation period, the patient developed severe manifestations of Graft-versus-host disease (GvHD) with predominant in-volvement of the gastrointestinal tract: severe diarrhoea, abdominal pain, weight loss, signs of dysbiosis, and nutritional deficiency. After ineffective therapy with steroids and supportive care, a decision was made to perform FMT using carefully selected donor material. Results. The FMT procedure was clinically successful, with improvements in general condition, a decrease in the severity of diarrhea, stabilization of body weight, and restoration of appetite noted within several days. Endoscopic and histological examinations of the intestinal mucosa confirmed a reduction in inflammatory changes. No side effects, complications, or signs of systemic infection were recorded after FMT. Conclusions. The successful application of FMT in this case demonstrates the potential of the meth-od as an additional therapeutic tool in (GvHD) with intestinal involvement, particularly in steroid-resistant forms of the disease
- 12 November 2025
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 77 (3) , 50-56
Open AccessSUCCESSFUL EXPERIENCE WITH FAECAL MICROBIOTA TRANSPLANTATION IN A PATIENT WITH MYELODYSPLASTIC SYNDROME AND GRAFT-VERSUS-HOST REACTION WITH INTESTINAL LESIONS COMBINED WITH ENTEROCOLITIS CAUSED BY CLOSTRIDIUM DIFFICILE INFECTION: A CLINICAL CASE
Relevance: Faecal microbiota transplantation (FMT) is the transfer of intestinal contents from a healthy donor to a patient to restore normal microflora. The material contains beneficial bacteria, fungi, antibodies, prebiotics, and other biologically active components. FMT is most effectively used for recurrent Clostridium difficile infection, showing better results compared to traditional treat-ment, such as vancomycin. Studies also suggest the potential of FMT in treating inflammatory bowel diseases, obesity, metabolic syndrome, and gastrointestinal tract functional disorders. In recent years, the method has gained widespread recognition and is now considered a potential first-line therapy for Clostridium difficile. The study aimed to present the first successful clinical experience of faecal microbiota transplanta-tion in a patient with myelodysplastic syndrome and graft-versus-host disease, characterized by in-testinal lesions. Methods: A clinical case of a 46-year-old patient who underwent allogeneic bone marrow trans-plantation for myelodysplastic syndrome is described. In the early post-transplantation period, the patient developed severe manifestations of Graft-versus-host disease (GvHD) with predominant in-volvement of the gastrointestinal tract: severe diarrhoea, abdominal pain, weight loss, signs of dysbiosis, and nutritional deficiency. After ineffective therapy with steroids and supportive care, a decision was made to perform FMT using carefully selected donor material. Results. The FMT procedure was clinically successful, with improvements in general condition, a decrease in the severity of diarrhea, stabilization of body weight, and restoration of appetite noted within several days. Endoscopic and histological examinations of the intestinal mucosa confirmed a reduction in inflammatory changes. No side effects, complications, or signs of systemic infection were recorded after FMT. Conclusions. The successful application of FMT in this case demonstrates the potential of the meth-od as an additional therapeutic tool in (GvHD) with intestinal involvement, particularly in steroid-resistant forms of the disease
- 30 September 2022
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 65 (3)
ACUTE KIDNEY INJURY IN PATIENTS WITH ACUTE LEUKEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SERIES OF CLINICAL CASES
Relevance: Acute renal kidney injury is a severe complication in patients with acute leukemia who underwent hematopoietic stem cell transplantation (HSCT). According to statistics, acute renal dysfunction often occurs in the first 100 days after HSCT. This study aimed to evaluate kidney function in patients with acute leukemia after hematopoietic stem cell transplantation. Methods: The article presents clinical cases of patients with acute lymphoblastic leukemia who developed acute renal failure after HSCT. The dynamics of the functional state of kidneys in patients with acute lymphoblastic leukemia after HSCT are described. Results: The acute kidney disorder in the studied patients was mainly caused by HSCT complications. We have identified renal kidney damage in the form of acute tumor lysis and thrombotic microangiopathy. Conclusion: Patients with acute lymphoblastic leukemia risk developing acute kidney disorder during HSCT, which requires careful monitoring of kidney function, especially in the early post-transplant period
- 30 September 2022
- Published by Kazakh Institute of Oncology and Radiology in Oncologia i Radiologia Kazakhstana
- Vol. 65 (3)
ACUTE KIDNEY INJURY IN PATIENTS WITH ACUTE LEUKEMIA AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SERIES OF CLINICAL CASES
Relevance: Acute renal kidney injury is a severe complication in patients with acute leukemia who underwent hematopoietic stem cell transplantation (HSCT). According to statistics, acute renal dysfunction often occurs in the first 100 days after HSCT. This study aimed to evaluate kidney function in patients with acute leukemia after hematopoietic stem cell transplantation. Methods: The article presents clinical cases of patients with acute lymphoblastic leukemia who developed acute renal failure after HSCT. The dynamics of the functional state of kidneys in patients with acute lymphoblastic leukemia after HSCT are described. Results: The acute kidney disorder in the studied patients was mainly caused by HSCT complications. We have identified renal kidney damage in the form of acute tumor lysis and thrombotic microangiopathy. Conclusion: Patients with acute lymphoblastic leukemia risk developing acute kidney disorder during HSCT, which requires careful monitoring of kidney function, especially in the early post-transplant period
- Open Access
- 14 December 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-10
First report from a single center retrospective study in Kazakhstan on acute myeloid leukemia treatment outcomes
Acute myeloid leukemia (AML) is the most common hematological malignancy in adults. In the last decade, internationally approved AML treatment guidelines, including hematopoietic stem cell transplantation are widely used in Kazakhstan. The categorization of acute myeloid leukemia was done according to the French-American British classification. The prognosis of patients at the time of diagnosis was determined by cytogenetic tests following the guidelines of the European LeukemiaNet. The overall survival and event-free survival were analyzed using the Kaplan–Meier method, and hazard ratios were defined with Cox regression. In total, 398 patients with AML were treated in the National Research Oncology Center between 2010 and 2020. The mean age was 38.3 years. We found a correlation between ethnicity, cytogenetic group, white blood cell count, and treatment approaches with overall and event-free survival. There was a significantly longer OS in a cytogenetic group with a good prognosis compared with intermediate and poor prognosis. The median survival time in the group with a good prognosis was 43 months, 23 months in the intermediate group (p = 0.7), and 12 months in the poor prognosis group (p = 0.016). There was a significantly longer OS for the group of patients who received hematopoietic stem cell transplantation (HSCT), 52 months versus 10 months in the group who received chemotherapy only, p-value < 0.0001. Prognostic factors, such as cytogenetic group, initial WBC count, and treatment approaches are significantly associated with patient survival. Our study data were consistent with the most recent studies, available in the literature adjusted for the population in question.
- 14 December 2021
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-10
Open AccessFirst report from a single center retrospective study in Kazakhstan on acute myeloid leukemia treatment outcomes
Acute myeloid leukemia (AML) is the most common hematological malignancy in adults. In the last decade, internationally approved AML treatment guidelines, including hematopoietic stem cell transplantation are widely used in Kazakhstan. The categorization of acute myeloid leukemia was done according to the French-American British classification. The prognosis of patients at the time of diagnosis was determined by cytogenetic tests following the guidelines of the European LeukemiaNet. The overall survival and event-free survival were analyzed using the Kaplan–Meier method, and hazard ratios were defined with Cox regression. In total, 398 patients with AML were treated in the National Research Oncology Center between 2010 and 2020. The mean age was 38.3 years. We found a correlation between ethnicity, cytogenetic group, white blood cell count, and treatment approaches with overall and event-free survival. There was a significantly longer OS in a cytogenetic group with a good prognosis compared with intermediate and poor prognosis. The median survival time in the group with a good prognosis was 43 months, 23 months in the intermediate group (p = 0.7), and 12 months in the poor prognosis group (p = 0.016). There was a significantly longer OS for the group of patients who received hematopoietic stem cell transplantation (HSCT), 52 months versus 10 months in the group who received chemotherapy only, p-value < 0.0001. Prognostic factors, such as cytogenetic group, initial WBC count, and treatment approaches are significantly associated with patient survival. Our study data were consistent with the most recent studies, available in the literature adjusted for the population in question.
- Open Access
- 17 April 2021
- Published by JSC National Scientific Medical Research Center in Journal of Clinical Medicine of Kazakhstan
- Vol. 18 (2) , 75-78
Case series of complex therapy of hemoblastosis in the context of COVID-19
Introduction: The COVID-19 pandemic is a problem of a global scale, and it has an importance in modern oncology and hematology. Patients with cancer are at high risk of getting infected with COVID-19. Diagnosis of coronavirus infection in such patients entails the cancellation of chemotherapy for an indefinite period. A break between courses of treatment, as well as a complete cancellation of therapy, can increase the mortality of patients from oncohematological diseases. Material and methods: From June to October 2020, based on the Oncohematological Department of the National Research Oncology Center LLP, 19 patients were treated, of which: men - 11, women - 8. Average age - 43 years (+ -16). Of these, patients with multiple myeloma - 32%; acute myeloid leukemia - 26%; acute promyelocytic leukemia - 11%; acute lymphoblastic leukemia - 26%; chronic lymphocytic leukemia - 5%. Treatment was carried out following the protocols for the diagnosis and treatment of hemoblastosis and concomitant COVID-19 infection. Results: This article presents clinical cases of complex therapy of patients with hemoblastosis and concomitant COVID-19 infection who were treated in a hospital.
- 17 April 2021
- Published by JSC National Scientific Medical Research Center in Journal of Clinical Medicine of Kazakhstan
- Vol. 18 (2) , 75-78
Open AccessCase series of complex therapy of hemoblastosis in the context of COVID-19
Introduction: The COVID-19 pandemic is a problem of a global scale, and it has an importance in modern oncology and hematology. Patients with cancer are at high risk of getting infected with COVID-19. Diagnosis of coronavirus infection in such patients entails the cancellation of chemotherapy for an indefinite period. A break between courses of treatment, as well as a complete cancellation of therapy, can increase the mortality of patients from oncohematological diseases. Material and methods: From June to October 2020, based on the Oncohematological Department of the National Research Oncology Center LLP, 19 patients were treated, of which: men - 11, women - 8. Average age - 43 years (+ -16). Of these, patients with multiple myeloma - 32%; acute myeloid leukemia - 26%; acute promyelocytic leukemia - 11%; acute lymphoblastic leukemia - 26%; chronic lymphocytic leukemia - 5%. Treatment was carried out following the protocols for the diagnosis and treatment of hemoblastosis and concomitant COVID-19 infection. Results: This article presents clinical cases of complex therapy of patients with hemoblastosis and concomitant COVID-19 infection who were treated in a hospital.
- 30 January 2021
- Published by Healthcare of Kazakhstan in International Professional Journal "Medicine"
- Vol. 11-12 (221-222)
Autologous hematopoietic stem cell transplantation in HIV-associated plasmablastic lymphoma: a case report
Plasmablastic lymphoma (PBL) is a disease that was originally described in 1997 as a distinct subtype of diffuse large B-cell lymphoma (DLBCL), which is more common in patients with HIV infection. It is characterized by extranodal lesions, the most common of which are the oral cavity, digestive tract, and skin3. No generally accepted chemotherapy protocol for the treatment of HIV-associated PBL has been developed. Early consolidation through autologous hematopoietic stem cell transplantation (auto-HSCT) may be a treatment option for advanced patients with concurrent use of highly active antiretroviral therapy (HAART). Disease history. Patient B., 44 years old, with HIV-associated PBL-IV-stage according to AnnArbor with lesions of the alveolar process of the upper jaw, lymph nodes of the neck on the left, bronchopulmonary lymph nodes, and the lower lobe of the right lung, who after 6 courses of chemotherapy according to the standard CHOP regimen, autotransplantation of hematopoietic stem cells was performed in the first remission. Conclusion. Our clinical experience correlates with the few studies on this issue. The patient received stem cell-supported high-dose chemotherapy (HDCT) and his life expectancy is 36 months. Keywords: plasmablastic lymphoma, HIV-associated lymphomas, autologous hematopoietic stem cell transplantation.
- 30 January 2021
- Published by Healthcare of Kazakhstan in International Professional Journal "Medicine"
- Vol. 11-12 (221-222)
Autologous hematopoietic stem cell transplantation in HIV-associated plasmablastic lymphoma: a case report
Plasmablastic lymphoma (PBL) is a disease that was originally described in 1997 as a distinct subtype of diffuse large B-cell lymphoma (DLBCL), which is more common in patients with HIV infection. It is characterized by extranodal lesions, the most common of which are the oral cavity, digestive tract, and skin3. No generally accepted chemotherapy protocol for the treatment of HIV-associated PBL has been developed. Early consolidation through autologous hematopoietic stem cell transplantation (auto-HSCT) may be a treatment option for advanced patients with concurrent use of highly active antiretroviral therapy (HAART). Disease history. Patient B., 44 years old, with HIV-associated PBL-IV-stage according to AnnArbor with lesions of the alveolar process of the upper jaw, lymph nodes of the neck on the left, bronchopulmonary lymph nodes, and the lower lobe of the right lung, who after 6 courses of chemotherapy according to the standard CHOP regimen, autotransplantation of hematopoietic stem cells was performed in the first remission. Conclusion. Our clinical experience correlates with the few studies on this issue. The patient received stem cell-supported high-dose chemotherapy (HDCT) and his life expectancy is 36 months. Keywords: plasmablastic lymphoma, HIV-associated lymphomas, autologous hematopoietic stem cell transplantation.